Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Editas Medicine Inc    EDIT

EDITAS MEDICINE INC

(EDIT)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/13/2019 05/14/2019 05/15/2019 05/16/2019 05/17/2019 Date
22.27(c) 22.49(c) 22.64(c) 23.19(c) 22.5(c) Last
1 034 094 1 037 104 984 201 631 492 582 702 Volume
-8.92% +0.99% +0.67% +2.43% -2.98% Change
More quotes
Financials (USD)
Sales 2019 20,3 M
EBIT 2019 -135 M
Net income 2019 -130 M
Finance 2019 188 M
Yield 2019 -
Sales 2020 20,4 M
EBIT 2020 -160 M
Net income 2020 -156 M
Finance 2020 241 M
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales2019 45,4x
EV / Sales2020 42,5x
Capitalization 1 108 M
More Financials
Company
Editas Medicine, Inc. is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based... 
More about the company
Surperformance© ratings of Editas Medicine Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on EDITAS MEDICINE INC
05/08EDITAS MEDICINE : Management's Discussion and Analysis of Financial Condition an..
AQ
05/07EDITAS : 1Q Earnings Snapshot
AQ
05/07EDITAS MEDICINE, INC. : Results of Operations and Financial Condition, Financial..
AQ
05/07EDITAS MEDICINE : Announces First Quarter 2019 Results and Update
AQ
04/30Editas Medicine to Host Conference Call Discussing First Quarter 2019 Results..
GL
04/29Allergan and Editas Medicine Announce Initial Data from Natural History Study..
GL
04/04EDITAS MEDICINE : and BlueRock Therapeutics Enter Strategic Research Collaborati..
AQ
04/03EDITAS MEDICINE : and BlueRock Therapeutics Enter Strategic Research Collaborati..
AQ
03/01EDITAS MEDICINE : Management's Discussion and Analysis of Financial Condition an..
AQ
02/28EDITAS MEDICINE, INC. : Entry into a Material Definitive Agreement, Results of O..
AQ
More news
Analyst Recommendations on EDITAS MEDICINE INC
More recommendations
Sector news : Biotechnology & Medical Research - NEC
05/15GILEAD SCIENCES : Novartis gets approval to sell Kymriah in Japan for $306,000
RE
05/13REGENERON PHARMACEUTICALS : Says FDA Approves Eylea Injection for All Diabetic R..
DJ
05/10PATRICK THOMAS : Biotech Industry Woos Talent With Top Pay -- WSJ
DJ
05/09PATRICK THOMAS : Biotech Is Place to Be for Top Salaries
DJ
05/08GLOBAL MARKETS LIVE : Siemens, Airbus, Nestlé, Tesla…
More sector news : Biotechnology & Medical Research - NEC
Chart EDITAS MEDICINE INC
Duration : Period :
Editas Medicine Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EDITAS MEDICINE INC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 42,3 $
Spread / Average Target 88%
EPS Revisions
Managers
NameTitle
Katrine S. Bosley President & Chief Executive Officer
James C. Mullen Chairman
Andrew A. F. Hack Chief Financial & Accounting Officer
Vic Myer Chief Technology Officer
Charles Albright Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
EDITAS MEDICINE INC-1.10%1 108
IQVIA HOLDINGS INC15.06%26 365
LONZA GROUP24.54%23 366
CELLTRION, INC.--.--%21 024
INCYTE CORPORATION21.40%16 555
EXACT SCIENCES CORPORATION52.44%12 422